Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account.

Verona Pharma Market & Company News

13.10.2020 07:00 Verona Pharma plc Verona Pharma to Present Phase 2b COPD Symptom and Quality of Life Data with Ensifentrine at CHEST 2020 GNW
23.09.2020 09:59 Verona Pharma PLC Verona Pharma launches trial of COPD treatment SMW
23.09.2020 09:06 Verona Pharma plc Verona Pharma Initiates Phase 3 Clinical Trials with Nebulized Ensifentrine for the Maintenance Treatment of COPD GNW
21.09.2020 09:41 Verona Pharma PLC Verona Pharma to disappear from AIM; focus on US listing SMW
21.09.2020 07:00 Verona Pharma plc Intended Delisting and Cancellation of Ordinary Shares from Trading on AIM GNW
17.09.2020 07:00 Verona Pharma plc Verona Pharma to Ring the Nasdaq Closing Bell to celebrate $200 million financing GNW
16.09.2020 13:25 Verona Pharma plc Verona Pharma Announces Publication of Phase 2b COPD Symptom Data in the International Journal of Chronic Obstructive Pulmonary Disease GNW
08.09.2020 07:00 Verona Pharma plc Verona Pharma Initiates Pilot Study with pMDI Ensifentrine in U.S. Patients Hospitalized with COVID-19 GNW
02.09.2020 07:00 Verona Pharma plc Verona Pharma to Present at H.C. Wainwright 22nd Annual Global Virtual Investment Conference GNW
26.08.2020 10:19 Verona Pharma plc Verona Pharma plc: Grant of RADSUs and PDMR Dealings GNW
24.08.2020 09:14 Verona Pharma PLC Verona Pharma to present COPD treatment trial analysis at conference SMW
24.08.2020 07:00 Verona Pharma plc Verona Pharma to Present Phase 2b data with Ensifentrine in COPD at the European Respiratory Society International Congress 2020 GNW
19.08.2020 07:56 Verona Pharma PLC Verona Pharma initiates delayed clinical trial for COPD treatment SMW
19.08.2020 07:00 Verona Pharma plc Verona Pharma Initiates Multiple Dose Part of Phase 2 Clinical Trial with pMDI Formulation of Ensifentrine in COPD GNW
14.08.2020 11:05 Verona Pharma PLC Second Price Monitoring Extn RNS
14.08.2020 11:00 Verona Pharma PLC Price Monitoring Extension RNS
14.08.2020 08:58 Verona Pharma PLC Verona Pharma to start Covid-19 treatment trial later in 2020 SMW
14.08.2020 07:00 Verona Pharma plc Verona Pharma plc Operational Update and Financial Results for the Three and Six Months Ended June 30, 2020 GNW
11.08.2020 06:15 Verona Pharma PLC Director Deals - Verona Pharma PLC (VRP) SMW
11.08.2020 06:15 Verona Pharma PLC Director Deals - Verona Pharma PLC (VRP) SMW
07.08.2020 15:46 Verona Pharma plc Verona Pharma plc: TR-1: Standard form for notification of major holdings GNW
04.08.2020 18:13 Verona Pharma plc Verona Pharma plc: Issue of Equity, PDMR Dealings & Total Voting Rights GNW
03.08.2020 07:00 Verona Pharma plc Verona Pharma Announces August 2020 Virtual Investor Conference Participation GNW
30.07.2020 10:52 Verona Pharma plc Verona Pharma plc: TR-1: Standard form for notification of major holdings GNW
30.07.2020 07:00 Verona Pharma plc Verona Pharma to Announce Interim Results for the Three and Six Months Ended June 30, 2020 and Provide Corporate Update GNW
27.07.2020 07:01 Verona Pharma plc Verona Pharma plc: TR-1: Standard form for notification of major holdings GNW
27.07.2020 06:15 Verona Pharma PLC Director Deals - Verona Pharma PLC (VRP) SMW
27.07.2020 06:15 Verona Pharma PLC Director Deals - Verona Pharma PLC (VRP) SMW
27.07.2020 06:15 Verona Pharma PLC Director Deals - Verona Pharma PLC (VRP) SMW
27.07.2020 06:15 Verona Pharma PLC Director Deals - Verona Pharma PLC (VRP) SMW
22.07.2020 16:50 Verona Pharma plc Closing of Financing, Issued Share Capital and Total Voting Rights GNW
17.07.2020 17:47 Verona Pharma plc Verona Pharma plc: PDMR Dealings GNW
17.07.2020 09:35 Verona Pharma PLC Verona Pharma raises $200m for trial of respiratory disease treatment SMW
17.07.2020 07:00 Verona Pharma plc Verona Pharma Raises $200 Million in Oversubscribed Private Placement and Subscription GNW
06.07.2020 16:04 Verona Pharma plc Verona Pharma plc: Issue of Equity and Total Voting Rights GNW
14.05.2020 07:00 Verona Pharma plc Verona Pharma Announces FDA Response to End-of-Phase 2 Briefing Package for Ensifentrine in COPD and Outlines Phase 3 ENHANCE Clinical Program GNW
12.05.2020 13:11 Verona Pharma plc Director/PDMR Shareholding - Grant of Restricted Stock Units, Issue of Equity, Total Voting Rights & PDMR Dealings GNW
01.05.2020 17:12 Verona Pharma plc Verona Pharma Presents Expanded Analysis of Ensifentrine Clinical Data in COPD Maintenance Treatment at the American Thoracic Society 2020 International Conference GNW
30.04.2020 10:00 Verona Pharma PLC Broker Forecast - Shore Capital issues a broker note on Verona Pharma PLC SMW
30.04.2020 07:00 Verona Pharma plc Verona Pharma plc: Operational Update and Financial Results for the Three Months Ended March 31, 2020 GNW
23.04.2020 07:00 Verona Pharma plc Verona Pharma to Announce Financial Results for the Three Months Ended March 31, 2020 and Provide Corporate Update GNW
16.04.2020 12:12 Verona Pharma plc Verona Pharma plc: Results of AGM GNW
08.04.2020 07:00 Verona Pharma plc Update on AGM Procedure GNW
31.03.2020 07:00 Verona Pharma plc Verona Pharma Reports Positive Efficacy and Safety Data with Single Dose pMDI Formulation of Ensifentrine in COPD GNW
20.03.2020 11:28 Verona Pharma plc Verona Pharma plc: Issue of Equity and Total Voting Rights GNW
17.03.2020 14:06 Verona Pharma PLC Second Price Monitoring Extn RNS
17.03.2020 14:01 Verona Pharma PLC Price Monitoring Extension RNS
16.03.2020 17:13 Verona Pharma plc 2019 Annual Report and Accounts and Notice of AGM GNW
05.03.2020 16:01 Verona Pharma plc Grant of Restricted Stock Units and PDMR Dealings GNW
27.02.2020 07:00 Verona Pharma plc Verona Pharma Reports Financial Results for the Full Year Ended December 31, 2019 and Provides Corporate Update GNW
Showing 1 to 50 of 637